Deepa Bhat


deepa.bhat.wg11@wharton.upenn.edu The Pennsylvania State University, University Park, PA


B.S., Schreyer Honors College Scholar, Animal Bioscience, 2004


Collin W. Blackburn


collin.blackburn.wg11@wharton.upenn.edu Harvard University, Cambridge, MA A.B., Cum Laude, Economics, 2004


David Brower


david.brower.wg11@wharton.upenn.edu Dartmouth College, Hanover, NH B.A., Biology, 2005


An opportunity to provide strategic leadership in a health care organization.


Genentech, South San Francisco, CA MBA Commercial Intern Lytics Marketing, Summer 2010 Created key customer engagement strategy to increase market penetra- tion across brand portfolio. Developed tactical recommendations in conjunc- tion with strategic brand plan and tactical planning to expand patient reach to organized stroke care.


Navigant Consulting, Inc., Chicago, IL Senior Consultant, 2007-2009


Developed operational and strategic recommendations for $1.1B payer, leading to 30% reduction in claims processing time and $900,000 in immediate cash benefit. Managed 6 member team to create and implement profit-maximizing strategies for hospital client.


The Central Intelligence Agency, McLean, VA Science, Weapons, Technology Analyst, 2005-2007


Customized written and verbal analyt- ic products for public health officials, military, and senior policymakers that addressed key intelligence questions and identified emerging develop- ments and trends in chemical and biological capabilities.


Milton S. Hershey Medical Center, Hershey, PA


Research Scientist, 2004-2005 Investigated toxicity of trial drug by analyzing 1,500 outcome data sets and identifying conclusive data trends, resulting in FDA approval for pre-clinical trial studies for diabetic patients.


An opportunity in the financial services sector with focus on the health care industry.


Greenhill & Co., San Francisco, CA Summer Associate, Summer 2010 Supported M&A transactions for companies in a variety of industries. Assisted the sell-side process of a European client engaged in the manufacture and distribution of defense equipment. Built financial models and analyzed various trans - action structures with emphasis on the Reverse Morris Trust.


UBS Investment Bank, London, UK Associate Director, 2008-2009 Associate, 2007-2008


Executed M&A and financing trans - actions for European clients in the pharmaceutical, medical devices, biotechnology, and health care servic- es industries. Performed all stages of the transaction process, including modeling, valuation, due diligence, drafting regulatory and marketing documents, and accompanying man- agement on investor presentations. Managed workflow for a team of 15 bankers as the Deputy Team Coordinator and Staffer.


UBS Investment Bank, San Francisco, CA Analyst, 2005-2007


Assisted the execution of M&A and financing transactions for small- and mid-cap health care companies in the medical devices industry. Performed valuation analyses, assessed market dynamics, and coordinated transaction logistics.


RBC Capital Markets, Boston, MA Analyst, 2004-2005


Assisted the execution of M&A and financing transactions for clients in the software industry.


8


An opportunity to apply my interests in medicine and business to the health care industry.


Weill Cornell Medical College, New York, NY Investigator, Research and Sponsored Project Group, 2009 Investigated conflicts of interest between the Medical College’s innovation-generating arm, medical researchers, and external entities (start-ups/VCs/biotech companies), working directly with each body for conflict resolution; member of four conflict of interest teams, each working to resolve particular cases.


Lehman Brothers (Barclays Capital), New York, NY Convertible Bond Trader, Healthcare Sector, 2005-2008


Acquired individual trading book and P&L March 2007, invested an average of $100M as one of four facilitation traders in all of Lehman convertibles. Maintained an average trading market share of 8%-10% versus Wall Street average of 4%-6% in 60 health care companies including medical technology, diagnostic, pharmaceuti- cal/biotechnology, and distributors. Generated trading profits of $500,000 on the date of St. Jude Medical’s new convertible issuance; became the trading volume market leader in Medtronic convertibles following Sprint Fidelis ICD lead fracture news in 2007, trading 30%+ daily market volume thereafter.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40